J&J OTC Business Returns To Double-Digit U.S. Growth In Q1
This article was originally published in The Tan Sheet
Executive Summary
The domestic OTC/nutritionals business grew more than 14% in the first quarter on the strength of McNeil products returning to market and a severe cold and flu season. Johnson & Johnson’s consumer performance exceeded some market analyst estimates.
You may also be interested in...
J&J Shines Spotlight On U.S. OTC Sales Growth
Domestic OTC sales grow nearly 20% to $644 million as J&J remains on track to return 75% of recalled McNeil products to market. Consumer business head Sandra Peterson says the firm began breaking out OTC sales figures to single out how the business is doing.
J&J Shines Spotlight On U.S. OTC Sales Growth
Domestic OTC sales grow nearly 20% to $644 million as J&J remains on track to return 75% of recalled McNeil products to market. Consumer business head Sandra Peterson says the firm began breaking out OTC sales figures to single out how the business is doing.
Perrigo Campaigns For Rational OTC Shopping Over Brand Loyalty
The online “Store Brand Meds” campaign launched by Perrigo in early 2013 encourages consumers to “Make store brands your brand,” by emphasizing lower price points and equivalent active ingredients. Overcoming consumer connections to brands such as Tylenol is a challenge, however.